Kyverna Therapeutics (KYTX) News Today $5.78 -0.71 (-10.94%) (As of 11:05 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Buy" by AnalystsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has received an average recommendation of "Buy" from the nine ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy reNovember 30 at 4:23 AM | marketbeat.comKyverna CMO Resignation Highlights Leadership Transition ImpactNovember 27, 2024 | markets.businessinsider.comResearch Analysts Offer Predictions for KYTX FY2024 EarningsNovember 23, 2024 | americanbankingnews.comWhat is HC Wainwright's Forecast for KYTX FY2024 Earnings?Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Investment analysts at HC Wainwright dropped their FY2024 EPS estimates for Kyverna Therapeutics in a research note issued to investors on Wednesday, November 20th. HC Wainwright analyst M. Kapoor now expects that the company will post earnNovember 22, 2024 | marketbeat.comMorgan Stanley’s Positive Outlook on Kyverna Therapeutics’ KYV-101 for Lupus NephritisNovember 21, 2024 | markets.businessinsider.comKyverna Therapeutics: Hold Rating Amid Financial Struggles and Inconclusive Clinical DataNovember 21, 2024 | markets.businessinsider.comKyverna Therapeutics price target lowered to $6 from $7 at H.C. WainwrightNovember 21, 2024 | markets.businessinsider.comOptimistic Buy Rating for Kyverna Therapeutics Driven by Promising KYV-101 Data and Pipeline ExpansionNovember 21, 2024 | markets.businessinsider.comHC Wainwright Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $6.00HC Wainwright reduced their target price on Kyverna Therapeutics from $7.00 to $6.00 and set a "neutral" rating on the stock in a research note on Wednesday.November 20, 2024 | marketbeat.cominstitutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% dropNovember 18, 2024 | finance.yahoo.comWhat is Leerink Partnrs' Forecast for KYTX FY2024 Earnings?Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Analysts at Leerink Partnrs upped their FY2024 earnings estimates for Kyverna Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($3.33) perNovember 18, 2024 | marketbeat.comKyverna Therapeutics price target lowered to $24 from $44 at Wells FargoNovember 16, 2024 | markets.businessinsider.comKyverna Therapeutics (NASDAQ:KYTX) Given New $24.00 Price Target at Wells Fargo & CompanyWells Fargo & Company lowered their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a report on Friday.November 15, 2024 | marketbeat.comKyverna Therapeutics Reports Q3 Loss Amid Rising R&D CostsNovember 15, 2024 | markets.businessinsider.comKyverna Therapeutics Advances in Cell Therapy LeadershipNovember 14, 2024 | markets.businessinsider.comKyverna Therapeutics anounces patient data on KYV-101November 14, 2024 | markets.businessinsider.comKyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024November 14, 2024 | prnewswire.comKyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | prnewswire.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Buy" from BrokeragesKyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has earned an average rating of "Buy" from the nine brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and oneNovember 5, 2024 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in OctoberKyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 2,490,000 shares, a growth of 9.7% from the September 30th total of 2,270,000 shares. Based on an average daily trading volume, of 404,600 shares, the days-to-cover ratio is currently 6.2 days. Currently, 14.1% of the company's stock are sold short.October 30, 2024 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Novo Holdings A SNovo Holdings A S raised its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 5.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,850,000 shares of the company's stock after buying an additional 100,000 shares during the quarter. NOctober 27, 2024 | marketbeat.comKyverna Therapeutics Strengthens Board with New AppointmentOctober 22, 2024 | markets.businessinsider.comKyverna Therapeutics Appoints Mert Aktar to its Board of DirectorsOctober 21, 2024 | prnewswire.comKyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell TherapyOctober 19, 2024 | msn.comMarshall Wace LLP Cuts Stock Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Marshall Wace LLP cut its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 93.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,400 shares of the company's stock after selling 145,355 shares durinOctober 14, 2024 | marketbeat.comUBS Initiates Coverage of Kyverna Therapeutics (KYTX) with Buy RecommendationOctober 11, 2024 | msn.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Buy" by BrokeragesKyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned an average rating of "Buy" from the nine brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one hasOctober 11, 2024 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Millennium Management LLCMillennium Management LLC boosted its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 32.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 923,082 shares of the company's stock after puOctober 11, 2024 | marketbeat.comJPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics IncOctober 11, 2024 | finance.yahoo.comKyverna Therapeutics (NASDAQ:KYTX) Receives New Coverage from Analysts at UBS GroupUBS Group began coverage on shares of Kyverna Therapeutics in a research report on Thursday. They set a "buy" rating and a $13.00 price objective on the stock.October 10, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated at Rodman & RenshawRodman & Renshaw initiated coverage on shares of Kyverna Therapeutics in a research note on Wednesday. They set a "buy" rating and a $16.00 price objective for the company.October 9, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comNovo Holdings A S Has $13.13 Million Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Novo Holdings A S raised its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 150.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,750,000 shares of the company's stock after purchasSeptember 30, 2024 | marketbeat.comMBB Public Markets I LLC Purchases Shares of 410,191 Kyverna Therapeutics, Inc. (NASDAQ:KYTX)MBB Public Markets I LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 410,191 shares of the company's stock, valued at approximately $3,076,000. MBB Public MaSeptember 29, 2024 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Deerfield Management Company L.P. Series CDeerfield Management Company L.P. Series C boosted its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 35.6% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 1,983,000 shares of the company's stock after purchasing an additional 520,663 sharesSeptember 26, 2024 | marketbeat.comAffinity Asset Advisors LLC Takes $1.50 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Affinity Asset Advisors LLC purchased a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the second quarter, according to its most recent filing with the SEC. The fund purchased 200,000 shares of the company's stock, valued at approximately $1,500,000. Affinity Asset AdvisSeptember 25, 2024 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Great Point Partners LLCGreat Point Partners LLC increased its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 232.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 499,152 shares of the company's stock after acSeptember 24, 2024 | marketbeat.comHold Rating Maintained for Kyverna Therapeutics Amidst Leadership Changes and Insufficient Clinical DataSeptember 19, 2024 | markets.businessinsider.comKyverna Therapeutics' (KYTX) Neutral Rating Reiterated at HC WainwrightHC Wainwright restated a "neutral" rating and issued a $7.00 price target on shares of Kyverna Therapeutics in a research note on Thursday.September 19, 2024 | marketbeat.comKyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024September 18, 2024 | prnewswire.comE Fund Management Co. Ltd. Acquires New Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)E Fund Management Co. Ltd. acquired a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 189,432 shares of the company's stock, vSeptember 18, 2024 | marketbeat.comKyverna Therapeutics Announces Leadership UpdateSeptember 16, 2024 | prnewswire.com90,242 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Purchased by TD Asset Management IncTD Asset Management Inc acquired a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 90,242 shares of the company's stock, valued at approximately $677,000. TD Asset ManagemenSeptember 16, 2024 | marketbeat.comKyverna Therapeutics: A Buy Rating for a Rising Star in CAR-T Therapy InnovationSeptember 14, 2024 | markets.businessinsider.comThe Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Violated Securities Laws And Investors Are Invited To ParticipateSeptember 11, 2024 | stockhouse.comLoad Up on Adobe Stock and These 2 Others This September, J.P. Morgan SaysSeptember 3, 2024 | barrons.comTG Therapeutics: Outpacing Skeptics With Briumvi's Growth Surge (Rating Upgrade)August 31, 2024 | seekingalpha.comThe Schall Law Firm Invites Shareholder Participation In An Inquiry Into Kyverna Therapeutics Inc For Securities Law InfractionsAugust 25, 2024 | stockhouse.comKyverna Therapeutics Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Investors Are Encouraged To ContributeAugust 24, 2024 | stockhouse.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Moderate Buy" by BrokeragesShares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating toAugust 22, 2024 | marketbeat.com Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. KYTX Media Mentions By Week KYTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYTX News Sentiment▼0.770.87▲Average Medical News Sentiment KYTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYTX Articles This Week▼33▲KYTX Articles Average Week Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCAX News COGT News ETNB News NUVB News COLL News IMTX News ZYME News AVBP News BCYC News PAHC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYTX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
